Primary tabs
0
Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): A single blind, randomized, non-inferiority trial (poster),
Pannus, Pieter, Depickère Stéphanie, Kemlin Delphine, Houben Sarah, Neven Christophe Y., Hendrickx Leo, Michiels Johan, Willems Elisabeth, De Craeye Stéphane, Francotte Antoine, et al.
, (0)
